Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue decreased by 10.6% to RMB 6,603.1 million compared to RMB 7,384.0 million in 2023[2]. - Gross profit fell by 21.3% to RMB 2,242.0 million, down from RMB 2,848.5 million in the previous year[2]. - Net profit attributable to the company's owners dropped by 80.0% to RMB 405.1 million, compared to RMB 2,024.8 million in 2023[2]. - The company's cash and cash equivalents decreased significantly by 72.3% to RMB 2,048.5 million from RMB 7,399.9 million[3]. - The gross profit margin declined to 34.0% from 38.6%, representing a decrease of 4.6 percentage points[2]. - The company's total revenue decreased by 10.6% from RMB 7,384.0 million to RMB 6,603.1 million during the reporting period[37]. - Revenue from the clinical trial technology services segment fell by 23.8% from RMB 4,168.1 million to RMB 3,178.1 million[39]. - Revenue from clinical trial-related services and laboratory services increased by 6.5% from RMB 3,215.9 million to RMB 3,425.0 million[37]. - Revenue in China decreased by 16.2% from RMB 4,234.5 million to RMB 3,547.9 million, primarily due to a decline in clinical trial technology services[37]. - Overseas revenue slightly decreased by 3.0% from RMB 3,149.5 million to RMB 3,055.2 million, but showed growth when excluding specific vaccine-related income[38]. - The net profit for the period dropped by 79.2% from RMB 2,149.9 million to RMB 447.8 million, with profit attributable to shareholders decreasing by 80.0% from RMB 2,024.8 million to RMB 405.1 million[73]. - The non-IFRS net profit attributable to shareholders, excluding non-recurring items, was RMB 854.9 million, a decrease of 42.1% compared to RMB 1,477.2 million in the same period last year, with a profit margin decline from 20.0% to 12.9%[79]. Industry Trends and Developments - The domestic biopharmaceutical industry is expected to recover, with the clinical research outsourcing market projected to grow at an average annual rate of 12.6% from 2024 to 2028, reaching approximately RMB 75 billion by 2028[6]. - In 2024, the National Medical Products Administration approved 48 new Class I innovative drugs, an increase of 8 compared to 2023, marking a historical high[7]. - The number of clinical trials for innovative drugs reached 1,859, positioning China as the second globally in the number of new drugs under development[7]. - The biopharmaceutical industry is transitioning from "scale expansion" to "value creation," indicating a shift towards high-quality innovation[8]. - The Chinese government has increased support for innovative drug development, with policies covering research, review, application, payment, and financing across the entire chain of innovative drug development[10]. - By 2025, the Chinese government plans to implement a multi-payment mechanism for innovative drugs, enhancing support for pharmaceutical productivity development[11]. - The trend of outbound licensing transactions reflects the global market's high recognition of Chinese innovative drug companies' research and development products[12]. - The focus on innovative drug development has been highlighted in the 2024 government work report, emphasizing the importance of this emerging industry[10]. - The clinical trial review and approval reform aims to complete the review of innovative drug clinical trial applications within 30 working days[10]. - The application of AI technology is expected to enhance efficiency and cost optimization in clinical trials, leading to significant innovations in existing service models of clinical CROs[131]. Company Strategy and Operations - The company plans to distribute a final dividend of RMB 3.0 per 10 shares for the fiscal year ending December 31, 2024[3]. - The company achieved a net new contract amount of RMB 8.4 billion in 2024, representing a year-on-year growth of 7.3%, with a total contract amount to be executed reaching RMB 15.8 billion, up 12.0% year-on-year[15]. - The number of new customers increased by 22% year-on-year, driven by improved customer management strategies[14]. - The company established a Clinical Operations Strategy Committee to enhance clinical project success rates and facilitate order conversion[16]. - The company expanded its overseas clinical CRO business, with new contracts, revenue, and profits all experiencing rapid growth in 2024[17]. - The company maintained its leading position in the Chinese clinical outsourcing service market, with a market share ranking first according to data from the Ministry of Science and Technology[13]. - The company actively explored business opportunities from large multinational pharmaceutical companies and overseas clinical research, contributing to its growth in the domestic market[15]. - The company aims to enhance its end-to-end service capabilities through a unified clinical research service platform and expand its business with multinational and large domestic pharmaceutical companies[25]. - The company is focusing on digitalization and AI technology to improve efficiency and automation in clinical research and biopharmaceuticals[28]. - The company has established a Digital Advancement Center to drive its digital and intelligent strategy, with plans to implement AI across various business operations by early 2025[31]. Financial Position and Investments - The company's total assets as of December 31, 2024, amounted to RMB 28,671,015,787.16, a decrease from RMB 29,680,742,349.17 at the end of the previous year, reflecting a decline of approximately 3.4%[178][180]. - Current assets decreased significantly to RMB 6,299,685,225.86 from RMB 11,344,141,125.21, representing a drop of about 44.5% year-over-year[178]. - The company's cash and cash equivalents fell to RMB 2,055,344,830.04, down from RMB 7,419,991,842.25, indicating a decrease of approximately 72.3%[178]. - Total liabilities decreased to RMB 4,606,536,600.57 from RMB 5,227,180,203.91, a reduction of about 11.9%[180]. - The company's equity attributable to shareholders decreased to RMB 20,670,653,449.72 from RMB 21,026,774,725.75, reflecting a decline of approximately 1.7%[180]. - Long-term equity investments increased to RMB 3,424.6 million, mainly due to an investment of RMB 500.0 million in Hangzhou Taikun Equity Investment Fund[96]. - The total outstanding borrowings as of December 31, 2024, were RMB 2,315.8 million, with a short-term borrowing portion of RMB 1,992.2 million and a long-term borrowing portion of RMB 323.6 million[103]. - The company plans to utilize proceeds from fundraising to expand and enhance clinical trial technical services, repay bank loans, and for general corporate purposes[127]. - The company has accumulated experience in over 4,000 clinical trial projects, including more than 910 Phase I clinical trials for Class 1 drugs in China and over 140 international multi-regional clinical trials[116]. Employee and Governance - The global employee count reached 10,185, with over 1,600 overseas employees, reflecting growth due to the acquisition of Shanghai Guanhua Medical Technology Co., Ltd.[24]. - The company has established a labor union in China to represent employees in the formulation of company policies and internal regulations[153]. - The company has adopted the corporate governance code and has complied with its principles and provisions during the reporting period[154]. - The company has implemented a competitive salary and benefits package to attract, motivate, and retain employees[153]. - The company has conducted regular reviews of its workforce to ensure optimal talent composition to meet service demands[153]. - The company recognizes the importance of high-quality and stable employees for delivering quality services to clients and is committed to improving recruitment and training programs[152]. Risks and Challenges - The company faces risks related to obtaining and maintaining necessary regulatory approvals, licenses, and permits, which could significantly disrupt operations if not secured[144]. - There is a risk of losing customers if their expectations are not met, potentially leading to a reduction in revenue and inability to attract new clients[145]. - The loss of major clients or contracts could have a substantial negative impact on the company's business and financial performance[146]. - The company is facing increased payment risks from some clients due to financial difficulties, leading to order cancellations[40]. - The global pharmaceutical contract research organization market is becoming increasingly competitive, and failure to effectively compete could lead to reduced revenue and profitability[141]. - The company plans to continue selective acquisitions and investments to drive growth, but failure to identify suitable targets could adversely affect financial results[147].

Financial Performance - For the six months ended June 30, 2024, the company's revenue was RMB 3,358.2 million, a decrease of 9.5% compared to RMB 3,710.9 million for the same period in 2023[8]. - Gross profit for the same period was RMB 1,333.0 million, down 10.0% from RMB 1,481.1 million year-on-year[8]. - Net profit attributable to the owners of the company was RMB 492.8 million, representing a significant decline of 64.5% from RMB 1,388.3 million in the previous year[8]. - The company's basic and diluted earnings per share were both RMB 0.57, a decrease of 64.6% compared to RMB 1.61 for the same period last year[8]. - The gross profit margin slightly decreased to 39.7% from 39.9% year-on-year[8]. - The net profit margin attributable to the owners of the company fell to 14.7% from 37.4% in the previous year, a decline of 22.7%[8]. - The adjusted net profit attributable to shareholders, excluding non-recurring items, was RMB 640.3 million, down 19.3% from RMB 793.5 million in the same period last year[8]. - The company did not declare any interim dividend for the six months ended June 30, 2024, consistent with the previous year[9]. Market and Strategic Focus - The company is focusing on enhancing its market presence and exploring new strategies for growth amid the declining financial performance[7]. - The board of directors has acknowledged the need for strategic adjustments to address the current market challenges and improve future performance[7]. - The company maintained a market share of 12.85% in the Chinese clinical outsourcing service market in 2023, ranking as the only Chinese contract research organization in the global top 10 with a market share of 1.46%[12]. - The company is focusing on early-stage investment opportunities in innovative biopharmaceutical and medical device startups to foster long-term partnerships and promote continuous innovation in the biopharmaceutical industry[82]. - The company aims to create a comprehensive lifecycle service platform for technology achievement transformation, integrating various resources for pharmaceutical innovation[82]. Clinical Trials and Research - In the first half of 2024, the number of new clinical trials initiated by the top 20 global pharmaceutical companies in China reached 293, accounting for 15.4% of global clinical trials, a significant increase from 9.8% in 2018[12]. - The number of ongoing drug clinical research projects increased from 772 as of June 30, 2023, and 752 as of December 31, 2023, to 800 as of June 30, 2024[12]. - The National Medical Products Administration approved 27 Class 1 innovative drugs in the first half of 2024, an increase of 4 compared to the same period in 2023[10]. - The number of clinical trials publicly announced by the China Center for Drug Evaluation reached 2,297 in the first half of 2024, an increase of 329 from the first half of 2023[10]. - The company provided services for 15 Class 1 innovative drugs approved in China in the first half of 2024 and assisted in the successful launch of 2 innovative medical device products[12]. Financial Assets and Investments - The total potential amount of overseas licensing transactions by Chinese biopharmaceutical companies reached $24.3 billion in the first half of 2024, representing a year-on-year growth of 110%[12]. - The company has committed additional capital of RMB 7 billion to invest in the joint venture Hangzhou Taikun as of June 30, 2024[69]. - The company's investment in non-listed equity increased by 6.6% to RMB 5,330.5 million from RMB 4,999.5 million, driven by continued investments in entities with growth potential and fair value gains of RMB 87.7 million[63]. - The investment in listed equity securities decreased by 58.4% to RMB 113.9 million from RMB 273.7 million, primarily due to a fair value loss of RMB 155.0 million during the reporting period[63]. - The company realized gains of RMB 69.3 million from exits in investments and funds, compared to RMB 152.3 million in the same period last year[63]. Employee and Operational Changes - The total number of employees decreased from 9,701 to 9,348, with a reduction in China due to strategic adjustments in response to industry cycles[15]. - The number of overseas employees increased from 1,632 to 1,722, reflecting the company's strategy to expand clinical operations and project management teams in key markets[17]. - The company established a Clinical Operations Strategy Committee to enhance clinical strategy capabilities and improve RFP success rates, leading to better order conversion[13]. - As of June 30, 2024, the US clinical operations team grew to nearly 100 employees, covering 42 cities across 21 states, with over 700 partnerships with clinical trial centers[13]. Risks and Compliance - The company faces risks from intensified competition in the global clinical contract research organization market, impacting pricing and profitability[93]. - Future business expansion and strategic implementation may face risks if not effectively managed, potentially affecting the company's financial performance[94]. - The company emphasizes the importance of compliance with current and future laws, regulations, and industry standards, as failure to do so could significantly impact its business, financial condition, and operational performance[95]. - The company requires multiple regulatory approvals, licenses, and certifications to operate, and failure to obtain or renew these could severely disrupt its business operations and financial performance[96]. - There is a risk of losing customers if they perceive that the services provided do not meet their expectations, which could adversely affect the company's revenue generation capabilities[97]. Shareholder and Governance - The company has approved a share repurchase plan with a total fund of no less than RMB 500 million and up to RMB 1 billion, with a maximum repurchase price of RMB 72.00 per share[160]. - The board approved the appointment of a new independent non-executive director on March 21, 2024, following the resignation of a previous director[163]. - As of June 30, 2024, Dr. Ye Xiaoping and Ms. Cao Xiaochun collectively hold 228,901,315 A shares, representing approximately 30.86% of the A shares and 26.46% of the total issued shares of the company[166]. - Major shareholders include 2017 Eagle Holdings LLC and F-J Sands Family I, LLC, each holding 14,606,581 H shares, which is 11.86% of the relevant class of shares and 1.69% of the total issued share capital[170]. - The company has adopted the principles and code provisions of the Corporate Governance Code and has complied with its provisions during the reporting period[173].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 3,358.2 million, a decrease of 9.5% compared to RMB 3,710.9 million in the same period of 2023[3] - Gross profit for the same period was RMB 1,333.0 million, down 10.0% from RMB 1,481.1 million year-on-year[3] - Net profit attributable to the company's owners was RMB 492.8 million, reflecting a significant decline of 64.5% from RMB 1,388.3 million in the previous year[3] - The net profit margin attributable to the company's owners decreased to 14.7% from 37.4% in the same period last year, a drop of 22.7 percentage points[3] - Clinical trial technical services revenue was RMB 1,637.1 million, down 22.2% from RMB 2,103.4 million in the same period last year[23] - Revenue from clinical trial-related and laboratory services increased by 7.1% to RMB 1,721.1 million, compared to RMB 1,607.5 million in the previous year[22] - Domestic business revenue was RMB 1,870.4 million, a decline of 10.4% from RMB 2,087.4 million year-on-year, primarily due to a drop in clinical trial technical services[22] - Overseas business revenue was RMB 1,487.8 million, down 8.4% from RMB 1,623.5 million, but showed growth when excluding specific vaccine project revenues[22] - Net profit for the period decreased by 60.4% year-on-year to RMB 557.6 million, with profit attributable to shareholders dropping by 64.5% to RMB 492.8 million[48] - Adjusted net profit attributable to shareholders, excluding non-recurring items, was RMB 640.3 million, with a net profit margin of 19.1%[52] Clinical Trials and Market Position - The number of new clinical trials in China reached 2,297 in the first half of 2024, an increase of 329 trials compared to the same period in 2023[6] - The proportion of new clinical trials initiated by the top 20 global pharmaceutical companies in China reached 15.4%, up from 9.8% in 2018[10] - The company's market share in China's clinical outsourcing service market was 12.85% in 2023, and it ranked as the only Chinese contract research organization in the global top 10 with a market share of 1.46%[12] - As of June 30, 2024, the number of ongoing drug clinical research projects increased to 800 from 772 as of June 30, 2023, and 752 as of December 31, 2023[12] - The company achieved significant growth in new orders, driven by demand from multinational pharmaceutical companies in China and Chinese companies' overseas needs, with a stable order demand from Chinese pharmaceutical and medical device companies[12] Strategic Developments - The company established a Clinical Operations Strategy Committee to enhance clinical strategy capabilities and improve the success rate of RFPs, while also creating business units in specific therapeutic areas such as cell and gene therapy, GLP-1, and radiopharmaceuticals[13] - The company expanded its clinical operations in North America, with nearly 100 employees covering 42 cities across 21 states, and established partnerships with over 700 clinical trial centers[15] - The company completed the acquisition of Medical Edge Co., Ltd. in Japan to strengthen its data management and clinical data services in the Asia-Pacific region[16] - The company acquired NAMSA's China branch and established a strategic cooperation agreement for exclusive and global collaboration[28] Employee and Operational Changes - The total number of employees decreased from 9,701 as of December 31, 2023, to 9,348 as of June 30, 2024, primarily due to strategic adjustments in response to industry cycles in China[19] - The company plans to continue expanding its clinical operations and project management teams in key overseas markets, increasing the number of overseas employees from 1,632 to 1,722[20] - The company has established a global workforce of 9,348 employees across 37 countries as of June 30, 2024, with its international headquarters set up in Hong Kong in 2023[85] Financial Position and Investments - The company's cash and cash equivalents are primarily held in RMB, with no use of financial instruments for hedging purposes as of June 30, 2024[59] - As of June 30, 2024, the total financial assets amounted to RMB 10,549.6 million, an increase from RMB 10,288.3 million as of December 31, 2023, representing a growth of 2.5%[69] - Long-term equity investments increased to RMB 3,518.4 million from RMB 2,977.0 million, primarily due to a RMB 500.0 million investment in Hangzhou Taikun Equity Investment Fund[67] - The company is a strategic investor in 181 innovative companies in the healthcare sector and a limited partner in 61 professional investment funds as of June 30, 2024[70] Risks and Challenges - The company faces risks from intensified competition in the global clinical contract research market, impacting pricing and service quality[104] - Compliance with evolving regulations and industry standards is critical, as failure to adapt could adversely affect the company's operations and financial performance[106] - The company faces risks related to obtaining and maintaining necessary regulatory approvals, licenses, and certifications, which could significantly disrupt operations if not secured[108] - There is a risk of losing major customers or contracts, which could adversely affect the company's business and financial performance if significant spending cuts or terminations occur[108] Shareholder Actions and Capital Management - The company plans to repurchase shares with a total amount not less than RMB 500 million and not exceeding RMB 1 billion, with a repurchase price capped at RMB 60.00 per share[90] - The company adjusted its share repurchase plan, increasing the maximum repurchase price from RMB 60.00 to RMB 72.00 per share, with a total repurchase amount of up to RMB 1 billion, potentially repurchasing approximately 13,888,888 shares, representing about 1.59% of the total issued shares[92] - The company terminated the 2022 A-share restricted stock incentive plan, resulting in the cancellation of all unvested restricted shares, which will not adversely affect the company's operations or future development[92] Cash Flow and Liquidity - The net cash generated from operating activities was RMB 177.3 million, down 52.7% from RMB 375.0 million year-on-year, primarily due to a 39.7% decrease in cash received from other operating activities[56] - The net cash used in investing activities increased by 552.2% to RMB 4,621.8 million, mainly due to cash payments for acquisitions rising from RMB 956.1 million to RMB 4,733.5 million[57] - The net cash generated from financing activities decreased to RMB 206.2 million from RMB 621.1 million, attributed to a significant drop in non-controlling interest contributions[57] Market Trends and Future Outlook - The global contract research organization (CRO) market size grew from USD 53.91 billion in 2018 to USD 82.11 billion in 2023, with projections to reach USD 106.45 billion by 2026[96] - The Chinese CRO market size increased from RMB 38.80 billion in 2018 to RMB 84.83 billion in 2023, with expectations to reach RMB 112.65 billion by 2026[97] - The company anticipates increased demand for clinical trials from foreign innovative drugs in China, as more multinational pharmaceutical companies are investing in R&D within the country[99] - The demand for outsourced R&D services in the biopharmaceutical sector is increasing due to rising R&D costs and the complexity of drug development[100]

Financial Performance - In 2023, the company's revenue increased to RMB 7,384.0 million, a year-on-year growth of 4.2% from RMB 7,085.5 million in 2022[5] - Adjusted net profit attributable to shareholders reached RMB 1,786.0 million, reflecting a year-on-year increase of 7.2%[5] - The gross profit for 2023 was RMB 2,820.6 million, a 1.3% increase compared to RMB 2,785.4 million in the previous year[12] - The net profit attributable to the company's owners was RMB 2,026.5 million, showing a slight increase of 0.5% from RMB 2,016.1 million in 2022[12] - The adjusted net profit attributable to the company's owners was RMB 1,786.0 million, reflecting a 7.2% increase from RMB 1,665.8 million in 2022[12] - The total order amount for 2023 was RMB 7,852 million, a decline of 18.8% compared to the previous year, primarily due to order cancellations and a significant drop in handling fees[23] - The company's backlog as of December 31, 2023, was RMB 14,080 million, reflecting a year-on-year increase of 2.1%[23] - The net profit for the year decreased by 5.7% to RMB 2,151.6 million, mainly due to increased sales costs and marketing expenses[62] - The effective tax rate rose from 12.1% to 13.6%, influenced by changes in certain other income items that were not fully taxable[61] Revenue Sources - Revenue from clinical trial technical services amounted to RMB 4,168.1 million, with a year-on-year growth of 1.0%[5] - Revenue from clinical trial-related services and laboratory services reached RMB 3,215.9 million, showing a year-on-year increase of 8.6%[5] - Clinical trial-related services and laboratory services generated revenue of RMB 3,215.9 million, an increase of 8.6% from RMB 2,960.3 million in the same period last year[40] Market Position and Growth - The company maintained its market leadership in China's clinical CRO industry, servicing 22 Class 1 new drugs and 6 innovative medical devices in 2023[5] - Cumulatively, the company has provided services for 61% of China's listed Class 1 new drug developments since its establishment in 2004[5] - The company is optimistic about the post-pandemic "new normal" and expects improvements in the industry environment in 2024[19][21] - The company continues to maintain its leading position in China's clinical contract research organization industry despite challenges from the COVID-19 vaccine revenue decline[23] - The company has achieved a market share of 61% in providing services for newly listed Class I drugs in China from 2004 to 2023[100] International Expansion - The company established an international headquarters in Hong Kong in 2023, expanding its global operational footprint to 28 countries with 1,632 overseas employees[6] - The company expanded its international operations, opening an international headquarters in Hong Kong and significantly increasing clinical trial service revenue in the U.S.[26] - The company has formed strategic alliances with 52 clinical trial excellence centers, establishing 224 core cooperation centers nationwide by December 31, 2023[101] Employee and Operational Growth - The company has over 9,000 employees contributing to its robust growth and resilience in a challenging environment[5] - The total number of employees increased to 9,701 as of December 31, 2023, up from 9,455 as of June 30, 2023, reflecting a growth strategy in key overseas markets[50] - The number of ongoing drug clinical research projects rose from 680 as of December 31, 2022, to 752 as of December 31, 2023[31] - The number of clients served by the registration team increased from 649 to 720, completing 1,009 project experiences, and assisting 9 products in obtaining approval in China in 2023[35] Research and Development - The company is advancing its three major development strategies: globalization, integration, and digitization[4] - The company plans to enhance its integrated R&D service platform and expand its global market share through acquisitions and partnerships with multinational pharmaceutical companies[22] - The company has established integrated R&D service platforms for pharmaceuticals and medical devices, covering the entire lifecycle from drug discovery to post-market studies[98] Financial Health and Investments - The total assets of the company as of December 31, 2023, were RMB 29,680.7 million, an 8.1% increase from RMB 27,446.5 million in 2022[13] - The company's cash and cash equivalents decreased by 4.9% to RMB 7,399.9 million from RMB 7,782.7 million in 2022[13] - The company realized gains of RMB 546.1 million from exits in investments during the reporting period, significantly higher than RMB 162.8 million in the same period last year[82] - The company is a strategic investor in 170 innovative companies in the healthcare sector and a limited partner in 55 professional investment funds as of December 31, 2023[81] Risks and Challenges - The company faces potential risks from natural disasters, pandemics, and other emergencies that could adversely affect its operations, financial condition, and performance[115] - A decline in demand for biopharmaceutical research services could significantly impact the company's business, financial condition, and performance if trends in the pharmaceutical market reverse[116] - Increased competition in the global clinical contract research organization market may lead to pricing pressure, affecting the company's revenue and profitability[117] - The company anticipates continued business growth, necessitating effective management of expansion strategies to avoid adverse impacts on its financial condition and performance[117] Corporate Governance - The company has a strong governance structure with independent directors overseeing financial and operational matters[143] - The board consists of seven members, including four executive directors and three independent non-executive directors, ensuring effective governance[154] - The company has adopted corporate governance practices in line with the principles outlined in the listing rules, maintaining high standards of governance[150] - The company emphasizes the importance of good corporate governance in enhancing management and protecting shareholder interests[150] Environmental, Social, and Governance (ESG) Initiatives - The company received an AAA rating from the Shenzhen Stock Exchange for its ESG governance and improved its MSCI ESG rating to AA[10] - The company published the "Tigermed ESG Guidelines," covering anti-corruption, employee rights, customer rights, environmental protection, and social welfare[190] - The company is committed to improving its ESG performance, with specific short-term and long-term improvement goals outlined[191]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,660,204,321.44, representing a decrease of 8.00% compared to the same period last year[10]. - Net profit attributable to shareholders for Q1 2024 was CNY 235,072,002.70, down 58.65% year-on-year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 303,052,196.14, a decrease of 20.50% compared to the previous year[10]. - Basic earnings per share for Q1 2024 were CNY 0.27, down 59.09% year-on-year[10]. - Operating profit for the current period was ¥362,196,228.41, a decline of 42.67% compared to ¥630,897,782.90 in the previous period[46]. - Net profit for the current period was ¥312,570,373.39, down 45.03% from ¥568,325,660.27 in the previous period[46]. - Total comprehensive income for the current period was ¥290,331,159.48, down 44.24% from ¥521,771,775.19 in the previous period[48]. - The company reported a decrease in investment income, recording a loss of ¥3,591,151.18 compared to a gain of ¥25,784,682.29 in the previous period[45]. Cash Flow - The net cash flow from operating activities increased significantly to CNY 144,204,460.07, up 405.83% from the same period last year[10]. - Net cash flow from operating activities rose significantly by 405.83% to 144,204,460.07 CNY, mainly due to reduced operating expenditures[19]. - Cash inflow from operating activities totaled $1.55 billion, a decrease of 4.94% compared to $1.63 billion in the previous period[52]. - Cash outflow from operating activities decreased to $1.41 billion from $1.60 billion, indicating better cost management[52]. - Investment activities generated a net cash flow of -$119.72 million, an improvement from -$547.51 million in the previous period[54]. - The net increase in cash and cash equivalents was $21.84 million, a turnaround from a decrease of $227.95 million in the previous period[55]. - The ending balance of cash and cash equivalents was $7.42 billion, slightly down from $7.55 billion in the previous period[55]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 30,070,185,491.17, an increase of 1.31% from the end of the previous year[10]. - Total current assets increased to ¥11,661,670,938.83 from ¥11,344,141,125.21, reflecting a growth of approximately 2.8%[37]. - Total non-current assets rose to ¥18,408,514,552.34 from ¥18,336,601,223.96, indicating an increase of approximately 0.4%[38]. - Total liabilities increased to ¥4,463,914,497.71 from ¥4,138,736,291.58, reflecting a growth of approximately 7.8%[40]. - Total liabilities increased to ¥5,536,893,616.67 from ¥5,227,180,203.91, reflecting a growth of 5.92%[42]. - Total equity attributable to shareholders of the parent company rose to ¥21,131,829,587.05 from ¥21,026,774,725.75, an increase of 0.50%[42]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,740[21]. - The top shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[23]. - The company has maintained a stable number of restricted shares at 171,687,044.00, with no new additions or removals during the reporting period[33]. Other Financial Metrics - Financial expenses increased by 37.34% to -21,920,357.75 CNY due to exchange rate fluctuations impacting foreign exchange gains[18]. - Other income surged by 198.25% to 15,369,745.78 CNY primarily from increased government subsidies received during the reporting period[18]. - Fair value changes in financial assets decreased by 92.77% to 12,753,272.78 CNY, attributed to declines in the stock prices of other non-current financial assets[18]. - Other comprehensive income after tax for the current period was -¥22,239,213.91, compared to -¥46,553,885.08 in the previous period[46]. Future Plans and Changes - The company plans to expand its market presence and enhance product offerings, although specific figures were not disclosed[34]. - The company plans to implement new accounting standards starting in 2024, which may impact financial reporting[56]. - The first quarter report was not audited, indicating preliminary financial results[56].

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 7,384.0 million, representing a 4.2% increase from RMB 7,085.5 million in 2022[2] - Adjusted net profit attributable to the company's owners increased by 7.2% to RMB 1,786.0 million from RMB 1,665.8 million in the previous year[2] - The company's net profit for the year decreased by 5.7% year-on-year from RMB 2,281.3 million to RMB 2,151.6 million, primarily due to increased sales costs and marketing expenses[47] - The profit attributable to the company's owners for 2023 was RMB 2,026.5 million, slightly up from RMB 2,016.1 million in 2022[52] - The company's gross profit was RMB 2,820.6 million, slightly up from RMB 2,785.4 million, with a gross margin decrease from 39.3% to 38.2%[35] - The company's total equity rose to RMB 24,453,562,000, an increase of 7.82% from RMB 22,681,028,000 in 2022[145] - The company's total assets as of December 31, 2023, amounted to RMB 25,542,006 thousand, up from RMB 23,716,941 thousand in 2022, reflecting a growth of 7.71%[134] Revenue Breakdown - Revenue from clinical trial-related services and laboratory services increased by 8.6% year-on-year, reaching RMB 3,215.9 million[19] - Revenue from the company's operations in China grew by 17.6% year-on-year, amounting to RMB 4,234.5 million, driven by its leading position in the clinical services market[19] - Revenue from clinical trial technical services was RMB 4,168,128,000, up from RMB 4,125,199,000, reflecting a growth of 1.04%[150] - Revenue from clinical trial related services and laboratory services increased significantly to RMB 3,215,911,000, a rise of 8.59% from RMB 2,960,272,000 in 2022[150] Assets and Liabilities - Total assets rose by 8.1% to RMB 29,680.7 million, compared to RMB 27,446.5 million in 2022[3] - The company's trade receivables and other receivables increased by 20.4% to RMB 1,428.2 million, driven by growth in business activities[59] - The company's contract assets rose by 18.4% to RMB 2,364.4 million, reflecting an increase in total contract amounts with clients[61] - The company's outstanding borrowings reached RMB 2,800.6 million as of December 31, 2023, with RMB 2,366.4 million classified as short-term borrowings[72] - The debt-to-equity ratio was reported at 11.5% as of December 31, 2023[73] Investments and Acquisitions - The company plans to enhance its end-to-end service capabilities and expand its global market share through mergers and acquisitions and by establishing business units based on therapeutic areas[11] - The company has committed additional capital of RMB 7.5 billion to invest in Hangzhou Taikun, a joint venture, as of December 31, 2023[77] - The company is a strategic investor in 170 innovative companies in the healthcare sector and a limited partner in 55 professional investment funds as of December 31, 2023[68] - The company plans to continue selective acquisitions and investments to achieve business growth, but failure to identify suitable targets or implement transactions successfully could adversely affect its financial performance[107] Research and Development - Research and development expenses increased by 11.5% year-on-year from RMB 234.6 million to RMB 261.6 million, attributed to a rise in the number of employees involved in R&D activities and their compensation[43] - The company has established integrated R&D service platforms for both pharmaceuticals and medical devices, covering the entire lifecycle of product development[85] - The company is investing heavily in R&D, with a budget allocation of 20 million USD for the development of new technologies[190] Market Trends and Outlook - The global pharmaceutical market is projected to reach approximately $1.6 trillion in 2023 and is expected to grow to $1.9 trillion by 2027, driven by aging populations and rising chronic non-communicable diseases[92] - The company anticipates further improvement in industry trends and the macro environment in the upcoming year[9] - Future outlook indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[190] Compliance and Governance - The company has adopted the principles and provisions of the corporate governance code and has complied with its provisions during the reporting period[115] - The board approved a proposal to change the use of proceeds to better allocate financial resources and seize domestic market opportunities[120] - The company is committed to adhering to international financial reporting standards to ensure transparency and accuracy in financial reporting[188] Employee and Talent Management - The total number of employees increased from 9,455 as of June 30, 2023, and 9,233 as of December 31, 2022, to 9,701 as of December 31, 2023[38] - Attracting, training, motivating, and retaining skilled personnel is essential for the company's success, especially in the competitive pharmaceutical and medical device sectors[108] - The company acknowledges the limited supply of qualified personnel in the industry, necessitating competitive compensation and benefits to attract and retain talent[108] Risks and Challenges - The company faces risks from potential natural disasters, pandemics, and regulatory changes that could impact operations and financial performance[99][101] - Increased competition in the global clinical contract research organization market may pressure pricing and affect revenue and profitability[101] - The company faces risks related to obtaining and renewing necessary regulatory approvals, licenses, and certifications, which are critical for its operations[105]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2023年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 749,293,420 | RMB | | | 1 RMB | | 749,293,420 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 749,293,420 | RMB | | | 1 RMB | | 749,293,420 | | 2. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2023年11月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 增加 / 減少 (-) | | | | 0 | | | RMB | | 0 | | 本月底結存 | | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 2. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第三季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 截至2023年9月30日止九個月第三季度報告。本公告及隨附的財務報表最初以中 文編製，並以中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本 為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 香港，2023年10月27日 於本公告日期，本公司執行董事為葉小平博士、曹曉春女 ...

杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第三次会议于 2023年10月27日在杭州市滨江区聚工路19号8幢19层会议室举行，本次会议以现场与通讯 表决相结合的方式召开。会议通知已于2023年10月13日以电话、电子邮件方式向全体董事 发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次会议的 召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 证券代码：300347 证券简称：泰格医药 公告编码（2023）032 号 杭州泰格医药科技股份有限公司 第五届董事会第三次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 具体内容详见中国证监会创业板指定信息披露网站同期披露的《公司2023年第三季度 报告》。 表决结果：同意7票，反对0票，弃权0票。 特此公告。 一、审议并通过《关于公司2023年第三季度报告的议案》。 杭州泰格医药科技股份有限公司董事会 二〇二三年十月二十八日 1 ...